Select a Region North America


Anne Marie Robertson

SVP, Strategy & Marketing


Brand Plan Development, Commercialization, Forecasting Activities, Launch Readiness, Management, Oncology, Patient Journey, Product Launch, Rare Disease

Anne Marie is helping EVERSANA deliver value to stakeholders across the life sciences industry. Through her multi-decade career at prominent large and small pharmaceutical companies, she has become a proven biopharma leader driving cross-functional teams. Specifically, Anne Marie has a record of successfully launching oncology therapies, such as Erbitux, Inlyta and Akynzeo, as well as developing new indications for in-market therapies. Her ability to set launch strategy and create science-based differentiation allows Anne Marie to leverage marketing strategies for clients globally while establishing and meeting launch metrics and driving overall brand value.

Anne Marie has an MBA from Baruch College of the City University of New York and a Bachelor of Science in biology from Rensselaer Polytechnic Institute. Early in her career Anne Marie was a U.S. Peace Corps Volunteer in Central Africa.

Articles by Anne Marie Robertson

Accelerated Approval Pathways: Manufacturers Left to Grapple With Risk Versus Reward

Oncology and hematology are extremely complex, crowded and chaotic therapeutic areas. With 30% of drug approvals by the FDA occurring in the oncology and hematology space, manufacturers of these high-science brands are often faced with unprecedented pressure to accelerate their speed to market to make a positive clinical impact on patients and the industry. To add an additional layer of complexity, manufacturers may opt to enter their product into a confirmatory trial, which allows the FDA to fast-track drug approvals in disease states where patients have little to no quality treatment options.   Accelerated pathways pose two key challenges:  The FDA is becoming more stringent, leading to an increased likelihood of […]

Pivot Pros: How EVERSANA Course Corrected When the Market Changed

Traditional commercialization models lack the insights, flexibility and agility to synthesize and react to real-time data. If you needed to quickly pivot your strategy to ensure the success of your therapy in market, would your commercialization partner be prepared to act in your best interest?   In this case study, EVERSANA’s oncology experts respond to a change in the marketplace to increase patient onboarding.  The Situation: New data post-launch changed the treatment landscape. Other therapies revealed strong survival in earlier lines of therapy, causing a change in the treatment sequence and shifting other products into later lines of therapy.     The Response: With the built-in flexibility of our COMPLETE Commercialization model, EVERSANA […]

Reversing the Complexity of Oncology Commercialization: How to solve for launch challenges in a chaotic ecosystem

As physicians, patients and caregivers tirelessly fight complex diseases, a growing number of drug manufacturers are preparing to launch new oncology therapies. These high-science therapies are entering the market at rapid rates: Presently, there are 500 active cell and gene therapy agents in clinical development, with a great momentum building for immuno-oncology treatments. The Oncology Ecosystem Is Changing, and the Cost for Commercialization Is Steep. There is no question about the incredible clinical impact these long-awaited therapies can have on patients and the industry, but launching in the oncology space is not the same as it was 20 years ago for two reasons: Commercialization stakes are high. The average cost […]

PharmaVOICE Webinar: Next Gen Commercialization Model for Oncology

In a new 60-minute virtual panel, “Next Gen Commercial Models in Oncology,” PharmaVOICE Editor Taren Grom sat down with industry leaders to discuss how changing market dynamics and a rich pipeline in oncology are creating a need for next gen commercial models.

Interested in scheduling a meeting or speaking event?


  • このフィールドは入力チェック用です。変更しないでください。